Agennix

Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

unknown title 2011

A live webcast will be available on the Agennix Web site at

unknown title 2011

Agennix initiated the OASIS Phase II/III trial in June 2011.

unknown title 2011

Agennix also reported data from an exploratory single center study, which was initiated prior to the establishment of Agennix AG and funded in part by a grant from the U.S. National Institutes of Health.

unknown title 2011

This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG, including statements about the Company's future cash position.

unknown title 2011

For additional information, please visit the Agennix Web site at

unknown title 2011

Agennix's registered seat is in Heidelberg, Germany.

unknown title 2011

Income tax benefit for the six months ended June 30, 2011, amounted to EUR 5.7 million EUR 3.9 million for the same period in 2010 and related to the deferred tax asset on net operating losses incurred by the Company's subsidiary, Agennix Incorporated, during the period.

unknown title 2011

As previously announced, the Company has scheduled a conference call to which participants may listen via live webcast, accessible through the Agennix Web site at

unknown title 2011

Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need.

unknown title 2011